MedTrace Logo

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

NCT01664247 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 346

Last updated 2017-09-25

Study results available
· View outcomes & findings →

Summary

This trial is conducted in Africa, Asia, Europe and North America. The purpose of the trial is to investigate the effect of insulin degludec (IDeg) in combination with liraglutide (Lira) and metformin (at least 1500 mg daily or maximum tolerated dose) in subjects with type 2 diabetes qualifying for treatment intensification.

Conditions

Interventions

DRUG

insulin degludec

Administered s.c. (under the skin) once daily. Dose individually adjusted.

DRUG

placebo

Administered s.c. (under the skin) once daily. Dose individually adjusted.

DRUG

liraglutide

Administered s.c. (under the skin) once daily. Dose: 1.8 mg.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-01
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States
  • Canada
  • France
  • Germany
  • Israel
  • Italy
  • Serbia
  • South Africa
  • Ukraine
  • United Arab Emirates
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01664247 on ClinicalTrials.gov